TFB Advisors’s Moderna MRNA Stock Holding History

TFB Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,632	Closed	-$313K	–	320
2024 Q2	$313K	Buy	2,632 +58	+2%	+$7.34K	0.1%	217
2024 Q1	$287K	Buy	+2,574	New	+$259K	0.1%	212

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TFB Advisors's MRNA Position: Q3 2024 in Review

TFB Advisors sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,632 shares — an estimated $313K sold.

TFB Advisors first reported a position in MRNA in Q1 2024 and held it in 2 quarters. The position peaked at $313K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

TFB Advisors reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
TFB Advisors sold 2,632 Moderna shares in Q3 2024, an estimated $313K.
TFB Advisors first reported a position in Moderna in Q1 2024 and held it in 2 quarters.
TFB Advisors's Moderna position peaked at $313K in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on TFB Advisors's 13F filing for Q3 2024, filed 31 Oct 2024.